Antitumor activity of cell-permeable p18 INK4c with enhanced membrane and tissue penetration

Junghee Lim, Jungeun Kim, Tam Duong, Guewha Lee, Junghee Kim, Jina Yoon, Jaetaek Kim, Hyuncheol Kim, H. Earl Ruley, Wael El-Rifai, Daewoong Jo

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Practical methods to deliver proteins systemically in animals have been hampered by poor tissue penetration and inefficient cytoplasmic localization of internalized proteins. We therefore pursued the development of improved macromolecule transduction domains (MTDs) and tested their ability to deliver therapeutically active p18 INK4c. MTD103 was identified from a screen of 1,500 signal peptides; tested for the ability to promote protein uptake by cells and tissues; and analyzed with regard to the mechanism of protein uptake and the delivery of biologically active p18 INK4c into cancer cells. The therapeutic potential of cell-permeable MTD103p18 INK4c (CP-p18 INK4c) was tested in the HCT116 tumor xenograft model. MTD103p18 INK4c appeared to traverse plasma membranes directly, was transferred from cell-to-cell and was therapeutically effective against cancer xenografts, inhibiting tumor growth by 86-98% after 5 weeks (P 0.05). The therapeutic responses to CP-p18 INK4c were accompanied by high levels of apoptosis in tumor cells. In addition to enhancing systemic delivery of CP-p18 INK4c to normal tissues and cancer xenografts, the MTD103 sequence delayed protein clearance from the blood, liver and spleen. These results demonstrate that macromolecule intracellular transduction technology (MITT), enabled by MTDs, may provide novel protein therapies against cancer and other diseases.

Original languageEnglish (US)
Pages (from-to)1540-1549
Number of pages10
JournalMolecular Therapy
Volume20
Issue number8
DOIs
StatePublished - Jan 1 2012
Externally publishedYes

Fingerprint

Membranes
Neoplasms
Heterografts
Proteins
Protein Sorting Signals
Blood Proteins
Therapeutics
Spleen
Cell Membrane
Apoptosis
Technology
Liver
Growth

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Lim, J., Kim, J., Duong, T., Lee, G., Kim, J., Yoon, J., ... Jo, D. (2012). Antitumor activity of cell-permeable p18 INK4c with enhanced membrane and tissue penetration. Molecular Therapy, 20(8), 1540-1549. https://doi.org/10.1038/mt.2012.102

Antitumor activity of cell-permeable p18 INK4c with enhanced membrane and tissue penetration. / Lim, Junghee; Kim, Jungeun; Duong, Tam; Lee, Guewha; Kim, Junghee; Yoon, Jina; Kim, Jaetaek; Kim, Hyuncheol; Ruley, H. Earl; El-Rifai, Wael; Jo, Daewoong.

In: Molecular Therapy, Vol. 20, No. 8, 01.01.2012, p. 1540-1549.

Research output: Contribution to journalArticle

Lim, J, Kim, J, Duong, T, Lee, G, Kim, J, Yoon, J, Kim, J, Kim, H, Ruley, HE, El-Rifai, W & Jo, D 2012, 'Antitumor activity of cell-permeable p18 INK4c with enhanced membrane and tissue penetration', Molecular Therapy, vol. 20, no. 8, pp. 1540-1549. https://doi.org/10.1038/mt.2012.102
Lim, Junghee ; Kim, Jungeun ; Duong, Tam ; Lee, Guewha ; Kim, Junghee ; Yoon, Jina ; Kim, Jaetaek ; Kim, Hyuncheol ; Ruley, H. Earl ; El-Rifai, Wael ; Jo, Daewoong. / Antitumor activity of cell-permeable p18 INK4c with enhanced membrane and tissue penetration. In: Molecular Therapy. 2012 ; Vol. 20, No. 8. pp. 1540-1549.
@article{6900eb0a3d0f48aebfdc14ab6c5878b4,
title = "Antitumor activity of cell-permeable p18 INK4c with enhanced membrane and tissue penetration",
abstract = "Practical methods to deliver proteins systemically in animals have been hampered by poor tissue penetration and inefficient cytoplasmic localization of internalized proteins. We therefore pursued the development of improved macromolecule transduction domains (MTDs) and tested their ability to deliver therapeutically active p18 INK4c. MTD103 was identified from a screen of 1,500 signal peptides; tested for the ability to promote protein uptake by cells and tissues; and analyzed with regard to the mechanism of protein uptake and the delivery of biologically active p18 INK4c into cancer cells. The therapeutic potential of cell-permeable MTD103p18 INK4c (CP-p18 INK4c) was tested in the HCT116 tumor xenograft model. MTD103p18 INK4c appeared to traverse plasma membranes directly, was transferred from cell-to-cell and was therapeutically effective against cancer xenografts, inhibiting tumor growth by 86-98{\%} after 5 weeks (P 0.05). The therapeutic responses to CP-p18 INK4c were accompanied by high levels of apoptosis in tumor cells. In addition to enhancing systemic delivery of CP-p18 INK4c to normal tissues and cancer xenografts, the MTD103 sequence delayed protein clearance from the blood, liver and spleen. These results demonstrate that macromolecule intracellular transduction technology (MITT), enabled by MTDs, may provide novel protein therapies against cancer and other diseases.",
author = "Junghee Lim and Jungeun Kim and Tam Duong and Guewha Lee and Junghee Kim and Jina Yoon and Jaetaek Kim and Hyuncheol Kim and Ruley, {H. Earl} and Wael El-Rifai and Daewoong Jo",
year = "2012",
month = "1",
day = "1",
doi = "10.1038/mt.2012.102",
language = "English (US)",
volume = "20",
pages = "1540--1549",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Antitumor activity of cell-permeable p18 INK4c with enhanced membrane and tissue penetration

AU - Lim, Junghee

AU - Kim, Jungeun

AU - Duong, Tam

AU - Lee, Guewha

AU - Kim, Junghee

AU - Yoon, Jina

AU - Kim, Jaetaek

AU - Kim, Hyuncheol

AU - Ruley, H. Earl

AU - El-Rifai, Wael

AU - Jo, Daewoong

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Practical methods to deliver proteins systemically in animals have been hampered by poor tissue penetration and inefficient cytoplasmic localization of internalized proteins. We therefore pursued the development of improved macromolecule transduction domains (MTDs) and tested their ability to deliver therapeutically active p18 INK4c. MTD103 was identified from a screen of 1,500 signal peptides; tested for the ability to promote protein uptake by cells and tissues; and analyzed with regard to the mechanism of protein uptake and the delivery of biologically active p18 INK4c into cancer cells. The therapeutic potential of cell-permeable MTD103p18 INK4c (CP-p18 INK4c) was tested in the HCT116 tumor xenograft model. MTD103p18 INK4c appeared to traverse plasma membranes directly, was transferred from cell-to-cell and was therapeutically effective against cancer xenografts, inhibiting tumor growth by 86-98% after 5 weeks (P 0.05). The therapeutic responses to CP-p18 INK4c were accompanied by high levels of apoptosis in tumor cells. In addition to enhancing systemic delivery of CP-p18 INK4c to normal tissues and cancer xenografts, the MTD103 sequence delayed protein clearance from the blood, liver and spleen. These results demonstrate that macromolecule intracellular transduction technology (MITT), enabled by MTDs, may provide novel protein therapies against cancer and other diseases.

AB - Practical methods to deliver proteins systemically in animals have been hampered by poor tissue penetration and inefficient cytoplasmic localization of internalized proteins. We therefore pursued the development of improved macromolecule transduction domains (MTDs) and tested their ability to deliver therapeutically active p18 INK4c. MTD103 was identified from a screen of 1,500 signal peptides; tested for the ability to promote protein uptake by cells and tissues; and analyzed with regard to the mechanism of protein uptake and the delivery of biologically active p18 INK4c into cancer cells. The therapeutic potential of cell-permeable MTD103p18 INK4c (CP-p18 INK4c) was tested in the HCT116 tumor xenograft model. MTD103p18 INK4c appeared to traverse plasma membranes directly, was transferred from cell-to-cell and was therapeutically effective against cancer xenografts, inhibiting tumor growth by 86-98% after 5 weeks (P 0.05). The therapeutic responses to CP-p18 INK4c were accompanied by high levels of apoptosis in tumor cells. In addition to enhancing systemic delivery of CP-p18 INK4c to normal tissues and cancer xenografts, the MTD103 sequence delayed protein clearance from the blood, liver and spleen. These results demonstrate that macromolecule intracellular transduction technology (MITT), enabled by MTDs, may provide novel protein therapies against cancer and other diseases.

UR - http://www.scopus.com/inward/record.url?scp=84864555062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864555062&partnerID=8YFLogxK

U2 - 10.1038/mt.2012.102

DO - 10.1038/mt.2012.102

M3 - Article

C2 - 22617107

AN - SCOPUS:84864555062

VL - 20

SP - 1540

EP - 1549

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 8

ER -